Will UK's IP Commercialization Model Go Trans-Atlantic Soon?
This article was originally published in Scrip
IP commercialization may be all the rage for company creation in the UK, but it remains comparatively unknown in the US. The CEOs of two Boston-based groups using that business approach – Allied Minds PLC and PureTech Health PLC – spoke to Scrip's sister publication Start-Up about their firms' strategies for creating and developing life science businesses using the model.
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.